Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Tricor adds tablets with HDL indication

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Tricor (fenofibrate) is approved Sept. 5 in two tablet strengths, 54 mg and 160 mg. Abbott's lipid-lowering agent was launched in 1998 as a 67 mg micronized capsule for treatment of type II, IV, and V hyperlipidemia and is also available as 134 mg and 200 mg capsules. The tablet formulation received approval for an additional claim that the capsule does not have: increasing HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia, according to the company
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel